Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.

Biotechnology

Education

Akero

Akero's headquarters in South San Francisco, CA, United States

Andrew Cheng

Kitty Yale

Maribel Rios

Scott Gangloff

Libette Luce

Tim Rolph

William White

Jonathan Young

Catriona Yale

Judy Chou

Mark Iwicki

Graham Walmsley

Seth L. Harrison

Tom Heyman

Yuan Xu

Jane Pritchett Henderson

The Clinical Research and Development team at Akero Therapeutics is responsible for designing, conducting, and overseeing clinical trials aimed at evaluating the safety and efficacy of efruxifermin (EFX) as a treatment for non-alcoholic steatohepatitis (NASH). This interdisciplinary team manages all aspects of clinical program execution, including protocol development, data management, statistical analysis, and ensuring regulatory compliance to advance Akero's drug candidates through the clinical pipeline.

Clinical Research and Development

The Financial and Accounting Team at Akero Therapeutics is responsible for managing the company's financial operations, including budgeting, forecasting, and financial reporting. They ensure compliance with regulatory requirements, oversee the financial planning and analysis (FP&A) for clinical trials, and provide strategic financial insights to support corporate development and the advancement of Akero's lead product candidate, efruxifermin (EFX), in its clinical trials.

Financial and Accounting Team

The Development Team at Akero Therapeutics is responsible for advancing the company's lead product candidate, efruxifermin (EFX), through the clinical development process. This includes overseeing the drug substance process development, managing clinical trial operations, developing medical devices related to the treatment, and ensuring optimal packaging and usability. The team, led by experienced leaders in drug development and engineering, focuses on translating research breakthroughs into effective, approved therapies for non-alcoholic steatohepatitis (NASH).

Development Team

The Leadership Team at Akero Therapeutics is responsible for setting the strategic direction of the company and overseeing its clinical development efforts in the pursuit of innovative treatments for non-alcoholic steatohepatitis (NASH). Comprising key executives such as the President & CEO, Chief Scientific Officer, and COO, this team collaborates to ensure efficient operations, drive fundraising, and advance the progress of their lead product candidate, efruxifermin (EFX), through clinical trials while maintaining high standards of quality and regulatory compliance.

Leadership Team

The Quality Control Team at Akero Therapeutics ensures the integrity and consistency of clinical trial materials and processes. They oversee the validation and regulation of critical reagents, maintaining high standards of quality for Akero's lead product candidate, efruxifermin (EFX). This team plays a crucial role in the success of Akero’s clinical-stage research by guaranteeing compliance with industry standards and regulatory requirements.

Akero

Org chart

Board & advisors

Teams

Clinical Research and Development

Financial and Accounting Team

Development Team

Leadership Team

Quality Control Team

Offices

Akero

Org chart

Board & advisors

Teams

Clinical Research and Development

Financial and Accounting Team

Development Team

Leadership Team

Quality Control Team

Offices

Related companies